BioSante shares surge on GVAX data for pancreatic cancer


Shares of BioSante ($BPAX) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a trial that recruited 30 patients. Story